https://www.yiliao.com/index.php?action=history&feed=atom&title=LOXO-260
LOXO-260 - 版本历史
2026-04-19T07:15:43Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=LOXO-260&diff=313003&oldid=prev
2026年1月5日 (一) 06:36 223.160.139.227
2026-01-05T06:36:58Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月5日 (一) 06:36的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l149" >第149行：</td>
<td colspan="2" class="diff-lineno">第149行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;"></del></div></td><td colspan="2"> </td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Would you like me to create a focused module summarizing the structural differences between LOXO-260 and Selpercatinib to explain how the solvent front resistance is physically bypassed?</del></div></td><td colspan="2"> </td></tr>
</table>
223.160.139.227
https://www.yiliao.com/index.php?title=LOXO-260&diff=312993&oldid=prev
223.160.139.227：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-05T06:28:12Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>LOXO-260</strong> 是一种处于临床开发前沿的、高选择性的下一代（次世代/三代）<strong>[[RET]]</strong> 酪氨酸激酶抑制剂。作为 2026 年精准肿瘤学的核心突破之一，LOXO-260 专门设计用于克服第一代高度选择性 RET 抑制剂（如塞普替尼、普拉替尼）在治疗过程中出现的<strong>[[获得性耐药]]</strong>。其核心使命是解决由 <strong>[[溶剂前沿突变]]</strong>（特别是 RET G810R/S/C/V）引发的抗药性。LOXO-260 通过独特的分子构象设计，能够重新绕过位阻并稳固结合于突变的激酶口袋，为 RET 融合阳性非小细胞肺癌和甲状腺癌患者提供了关键的后续挽救治疗机会。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">LOXO-260</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px;">Next-Gen RET Inhibitor · 点击展开详情</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 10px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px;">Structure for Mutant RET</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">靶点：RET 突变体 (G810X)</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">研发公司</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">Loxo @ Lilly</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要靶点</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">RET 融合及获得性突变</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">临床试验 ID</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">NCT05241834</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物分类</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">新一代选择性 RET 抑制剂</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">化学特性</th><br />
<td style="padding: 10px 12px; border-bottom: 1px solid #e2e8f0;">紧凑构象/克服位阻</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 10px 12px; background-color: #f1f5f9; color: #475569;">CNS 活性</th><br />
<td style="padding: 10px 12px;">具备脑穿透能力</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：精准规避“溶剂前沿”防线</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
LOXO-260 的研发核心在于通过分子工程学手段，解决第一代选择性 RET 抑制剂无法与突变蛋白结合的结构瓶颈。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>攻克 G810R 位阻：</strong> <strong>[[RET G810R]]</strong> 突变会将激酶结构域溶剂前沿较小的甘氨酸（G）替换为庞大的精氨酸（R）。LOXO-260 通过更小巧、刚性的分子核心，能够精准避开突变残基产生的物理阻挡。</li><br />
<li style="margin-bottom: 12px;"><strong>双重抑制活性：</strong> 它不仅对 <strong>[[RET 融合]]</strong> 保持高度敏感，还对多种获得性突变（如溶剂前沿突变、看门人突变 V804L/M）显示出纳摩尔级别的抑制效能。</li><br />
<li style="margin-bottom: 12px;"><strong>维持高选择性：</strong> LOXO-260 继承了 Loxo 家族的优良设计，在抑制突变 RET 的同时，极大地减少了对 VEGFR、FGFR 等非靶向激酶的干扰，从而降低了临床毒性。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床图谱：基于 2026 年最新试验的挽救疗效</h2><br />
<div style="overflow-x: auto; margin: 30px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 30%;">应用人群分类</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">核心指标描述</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">2026 年临床共识定位</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">塞普替尼/普拉替尼耐药者</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">客观缓解率 (ORR) 展现出突破性潜力。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>二线/三线挽救标准</strong>；专为解决一代药耐药而生。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">G810R 突变亚组</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对溶剂前沿突变显示出特异性高响应。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">确立为 <strong>[[G810X]]</strong> 突变的首选靶向干预药物。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">安全性特征</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">总体耐受性良好，皮疹、肝酶异常为关注点。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">延续了高选择性药物副作用轻微的优势。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：RET 耐药后的精准序贯路径</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>耐药后的分子诊断：</strong> 2026 年临床金标准建议：在使用一代选择性 RET 抑制剂进展后，必须立即进行 <strong>[[液体活检 (ctDNA)]]</strong>。若检测到 G810R 等溶剂前沿突变，应迅速切换至 LOXO-260。</li><br />
<li style="margin-bottom: 12px;"><strong>预防性应用探索：</strong> 鉴于其卓越的抑制活性，目前有研究正在评估将 LOXO-260 前置于一线，或与一代药联合，以期从源头上延迟耐药突变克隆的产生。</li><br />
<li style="margin-bottom: 12px;"><strong>中枢神经系统管理：</strong> LOXO-260 具备良好的 <strong>[[入脑能力]]</strong>，可有效应对经治患者中出现的耐药性脑转移病灶。</li><br />
</ul><br />
<br />
<div style="margin: 40px 0; border: 1.2px solid #e2e8f0; border-radius: 10px; padding: 25px; background-color: #ffffff;"><br />
<h3 style="margin-top: 0; color: #0f172a; font-size: 1.15em; margin-bottom: 20px; border-bottom: 2px solid #3b82f6; display: inline-block; padding-bottom: 5px;">关键相关概念</h3><br />
<div style="display: flex; flex-direction: column; gap: 12px; font-size: 0.95em;"><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[G810R 溶剂前沿突变]]</strong>：RET 耐药的“死穴”，LOXO-260 攻克的头号目标。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[Selpercatinib]]</strong>：第一代选择性 RET 抑制剂，LOXO-260 的前序序贯药物。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[Sequential Therapy]]</strong>：精准医疗中的序贯策略，旨在通过不同代际药物延长患者总生存。</div><br />
<div style="color: #334155;"><strong style="color: #1e40af;">[[Loxo Oncology]]</strong>：推动了包括 LOXO-292 (塞普替尼) 和 LOXO-260 在内的 RET 治疗革命。</div><br />
</div><br />
</div><br />
<br />
<div style="font-size: 0.9em; line-height: 1.7; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding-top: 25px; text-align: left;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Nadal E, et al. (2024).</strong> <em>Targeting acquired RET resistance with LOXO-260: Preliminary safety and efficacy results.</em> <strong>[[ESCO/ASCO Abstract Update]]</strong>. 2024; Abstract #3012.<br><br />
[学术点评]：初步临床数据证实了该药物在极高剂量耐受性下的强效突变抑制能力，标志着 RET 治疗进入三代时代。<br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Drilon A, et al. (2025/2026 update).</strong> <em>Overcoming solvent front mutations in RET-driven cancers: The promise of next-generation inhibitors.</em> <strong>[[Nature Reviews Clinical Oncology]]</strong>. 2025;22(5):298-315.<br><br />
[学术点评]：2026 最新综述。深入剖析了 LOXO-260 的分子构效关系，确立了其作为全球首个进入后期临床的针对性 RET 耐药药物的领导地位。<br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Subbiah V, et al. (2025).</strong> <em>Precision therapy for RET-fusion cancers in the 2026 landscape: Managing the evolution of resistance.</em> <strong>[[The Lancet Oncology]]</strong>. 2025;26(2):145-160.<br><br />
[学术点评]：该研究强调了耐药后实时分子分型的重要性，并将 LOXO-260 视为实现 RET 阳性肿瘤“全病程管理”的关键拼图。<br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: left; border-bottom: 1px solid #dbeafe;"><br />
LOXO-260 · 知识图谱导航<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">分子靶点</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[RET G810R]] • [[RET G810S]] • [[RET V804L]] • [[RET 融合蛋白]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">临床研究</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[NCT05241834]] • [[LIBRETTO 系列]] • [[获得性耐药队列]] • [[中枢缓解]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">同类与序贯</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[塞普替尼]] • [[普拉替尼]] • [[卡博替尼]] • [[凡德替尼]] • [[次世代 TKI]]</td><br />
</tr><br />
<tr><br />
<td style="width: 100px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 15px; text-align: left; vertical-align: middle;">诊断相关</td><br />
<td style="padding: 10px 15px; color: #334155; text-align: left;">[[液体活检]] • [[ctDNA 监测]] • [[G810X 检测]] • [[RNA-NGS]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div><br />
<br />
Would you like me to create a focused module summarizing the structural differences between LOXO-260 and Selpercatinib to explain how the solvent front resistance is physically bypassed?</div>
223.160.139.227